April 20, 2026 U.S. House of Representatives Washington, D.C. 20515 Dear Representative, On behalf of the more than one million members and supporters of the Council for Citizens Against Government Waste (CCAGW), I am pleased to provide you with Citizens Against Government Waste’s public comments to the Health Resources and Services Administration regarding their request […]
April 20, 2026 U.S. Senate Washington, D.C. 20510 Dear Senator, On behalf of the more than one million members and supporters of the Council for Citizens Against Government Waste (CCAGW), I am pleased to provide you with Citizens Against Government Waste’s public comments to the Health Resources and Services Administration regarding their request for information […]
President Trump has made lowering drug prices and reducing healthcare costs for Americans a top priority of his second term, along with encouraging more biopharmaceutical investment and innovation in the U.S. Citizens Against Government Waste suggests that he can achieve both objectives without imposing price controls, which includes Most Favored Nation (MFN) polices, reforming the […]
The 340B Drug Discount Program was created in 1992 to help federally funded clinics and public hospitals that serve a large uninsured population cover the cost of drugs and provide discounts to patients. But the lack of guardrails on the program and failure to define a patient has led to it being abused by hospitals […]
The federal 340B Drug Pricing Program was intended to provide discounts on drugs to patients but the lack of a clear intent and patient definition, along with inadequate oversight, has led to the program being exploited by hospitals and contract pharmacies to generate millions of dollars in profit. The discounts are supposed to be provided […]
This Week in Waste highlights how taxpayer dollars are being wasted and efforts to fight back against this waste.
President Trump’s EO addresses the dual objectives of lowering drug prices while promoting innovation and protecting IP
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
Pharmaceutical price controls in President Biden’s budget and the SMART Choices Act will devastate drug development.
Nevada State Assembly 401 South Carson Street Carson City, Nevada 89701-4747 Dear Assembly Member, AB 215, a so-called pharmaceutical price transparency bill, was introduced on February 13, 2017 and is currently being considered by the Assembly Committee on Health and Human Services. It would require pharmaceutical companies to provide to the Division of Insurance an […]
